Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | RARA | P10276 | 7/20 | 0.55 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.55 |
| ▸ | RXRA | P19793 | 6/20 | 0.53 |
| ▸ | RARB | P10826 | 5/20 | 0.53 |
| ▸ | RARG | P13631 | 5/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | RXRB | P28702 | 3/20 | 0.53 |
| ▸ | RXRG | P48443 | 3/20 | 0.53 |
| ▸ | RORC | P51449 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407627 | 1.00 | MAPT (0.65) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL1718771 | 0.93 | ALDH1A1 (0.65) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL1718768 | 0.93 | ALDH1A1 (0.65) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL1717617 | 0.89 | ALDH1A1 (0.50) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL1717620 | 0.89 | ALDH1A1 (0.50) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL10067414 | 0.88 | MAPT (0.50) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL5077672 | 0.83 | ALDH1A1 (0.74) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL4389193 | 0.83 | ALDH1A1 (0.74) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL10067418 | 0.83 | ALDH1A1 (0.55) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL1717884 | 0.83 | CYP26A1 (0.45) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420610-B2 | Polyunsaturated compounds, method for preparing same and compositions containing the same | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-04-16 | — | — | US | claimed |
| US-20100168045-A1 | Novel Polyunsaturated Compounds, Method for Preparing Same and Compositions Containing the Same | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2010-07-01 | — | — | US | claimed |
| US-8420610-B2 | Polyunsaturated compounds, method for preparing same and compositions containing the same | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20100168045-A1 | Novel Polyunsaturated Compounds, Method for Preparing Same and Compositions Containing the Same | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168045-A1 | Novel Polyunsaturated Compounds, Method for Preparing Same and Compositions Containing the Same | CBR3, CBR1, DECR1 | MAPT 4344/4885ALDH1A1 396/4885SMN1; SMN2 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.